Online inquiry

IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4037MR)

This product GTTS-WQ4037MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ4037MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2114MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ14814MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SGN-70
GTTS-WQ6192MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ7818MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK 716155
GTTS-WQ10274MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LFG 316
GTTS-WQ12847MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ14519MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ12160MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-009
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW